Despite Hybio Pharmaceutical's share price surge, its high P...
Despite Hybio Pharmaceutical's share price surge, its high P/S ratio and declining medium-term revenue could risk shareholders' investments. If the P/S aligns with recent negative growth rates, investors may face disappointment.
![](https://pubimg-10000538.picsh.myqcloud.com/202205090000029640145feb4f1.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment